Evidence map›Paper›PMID 24396486›Full record

ArticleOncology letters2014

Leena-Maija Soveri, Pia Osterlund, Tarja Ruotsalainen, Tuija Poussa, Hilpi Rautelin, Petri Bono

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Leena-Maija SoveriDepartment of Oncology, Helsinki University Central Hospital, Helsinki 00029, Finland.
Pia OsterlundDepartment of Oncology, Helsinki University Central Hospital, Helsinki 00029, Finland ; Clinical Department, University of Helsinki, Helsinki 00014, Finland.
Tarja RuotsalainenDepartment of Oncology, Helsinki University Central Hospital, Helsinki 00029, Finland.
Tuija PoussaSTAT-Consulting, Nokia 37130, Finland.
Hilpi RautelinDepartment of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki 00014, Finland ; HUSLAB, Helsinki University Central Hospital Laboratory, Helsinki 00029, Finland ; Uppsala University, Department of Medical Sciences, Uppsala 75185, Sweden.
Petri BonoDepartment of Oncology, Helsinki University Central Hospital, Helsinki 00029, Finland ; Clinical Department, University of Helsinki, Helsinki 00014, Finland.
Helsinki University Hospital · FIStatistics Finland · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-Fluorouracil (5-FU)-based chemotherapy is the mainstay of adjuvant treatment for colorectal cancer (CRC). Few studies have explored

Indexed as

adjuvant treatmentcolorectal cancergastrointestinal symptomsHelicobacter pylori

Identifiers

PMID24396486
PMCPMC3881927
OpenAlexW1973007414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.